<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200501047257N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-18</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of misoprostol on cesarean bleeding</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of sublingual mesoprostol, rectal and venous oxytocin on cesarean uterine bleeding</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-05-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>180</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/47720</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To allocate groups via permutation block randomization will be used, patients in the study using the blocks 6 each using the letters A, B, and C (for equality groups), the patients into 3 groups of 6 people divided . For permutation block randomization method of sealed envelopes with random sequences will be used, Blinding description: In this study, blindness is performed for statistical counselors as statistical counselors are not aware of the type of data they perform for analysis and only the data are identified by three groups A, B and C, and they are named by groups. And the method of intervention is unknown.</study_design>
      <phase>3</phase>
      <hc_freetext>The amount of bleeding from a cesarean section.</hc_freetext>
      <i_freetext>Intervention 1: First intervention group: After umbilical cord clamping during surgery, the patient will receive 20 oxytocin units within half a liter of Ringer's serum at a rate of 15 cc per minute.In the first intervention group, we place 200 micrograms of misoprostol in the patient's sublingual (It should be noted that Mizoprostol 100 mg tablets are from Abu Reihan Company and 10 units of Oxytocin ampoules are from Alborz Daroo Company).  If proper uterine contraction does not occur after a few minutes (maximum 5 minutes), if the initial intervention is not enough, oxytocin will be repeated up to 100 units (inside the Ringer's serum) and if we need more medication, misoprostol. We continue up to 1000 micrograms. Intervention 2: Second intervention group: After umbilical cord clamping during surgery, the patient will receive 20 oxytocin units within half a liter of Ringer's serum at a rate of 15 cc per minute.In the second intervention group, we place 200 micrograms of misoprostol in the patient's rectal area (It should be noted that Mizoprostol 100 mg tablets are from Abu Reihan Company and 10 units of Oxytocin ampoules are from Alborz Daroo Company). If proper uterine contraction does not occur after a few minutes (maximum 5 minutes), if the initial intervention is not enough, oxytocin will be repeated up to 100 units (inside the Ringer's serum) and if we need more medication, misoprostol. We continue up to 1000 micrograms. Intervention 3: Control group: After umbilical cord clamping during surgery, the patient will receive 20 oxytocin units within half a liter of Ringer's serum at a rate of 15 cc per minute(It should be noted that the oxytocin ampoule is 10 units from Alborz Daroo Co.) . If proper uterine contraction does not occur after a few minutes (maximum 5 minutes), oxytocin is repeated for up to 100 units (inside the Ringer's serum).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The data has not yet been determined</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Zahra Bagheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Gorgan Jadid First Street, 1st Alley, in front of Rosta Complex, two-storey private house</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4913714861</zip>
        <telephone>+98 17 3223 3381</telephone>
        <email>bagheri.z1994@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hooshang Akbari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Sari, Imam Square, Joibar Three Ways, at the beginning of Valiasr Highway, Central Headquarters of Mazandaran University of Medical Sciences</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815733971</zip>
        <telephone>+98 11 3304 4000</telephone>
        <email>hooshangakbari48@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients between the ages of 18 and 40
Candidates for cesarean section
Gestational age between 37 and 40 weeks
Candidates for Spinal anesthesia
Written consent from the patient
Single pregnancy
Low transverse uterine incision</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of PPH (postpartum hemorrhage)
Placenta previa and acarta
Liver or kidney disease
Eclampsia and preeclampsia
Epilepsy
Height below 155 cm
Obesity (BMI&gt; 40) ( BMI = Body mass index)
Infant weight over 4 kg
Polyhydramnios (increased amniotic fluid)
Patients received Anti-coagulation drugs
Patients with heart and lung problems and underlying diseases such as diabetes, high blood pressure (140/90 mm Hg), chronic anemia, coagulation disorders and immunodeficiency</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First intervention group: After umbilical cord clamping during surgery, the patient will receive 20 oxytocin units within half a liter of Ringer's serum at a rate of 15 cc per minute.In the first intervention group, we place 200 micrograms of misoprostol in the patient's sublingual (It should be noted that Mizoprostol 100 mg tablets are from Abu Reihan Company and 10 units of Oxytocin ampoules are from Alborz Daroo Company).  If proper uterine contraction does not occur after a few minutes (maximum 5 minutes), if the initial intervention is not enough, oxytocin will be repeated up to 100 units (inside the Ringer's serum) and if we need more medication, misoprostol. We continue up to 1000 micrograms</i_keyword>
      <i_keyword>Second intervention group: After umbilical cord clamping during surgery, the patient will receive 20 oxytocin units within half a liter of Ringer's serum at a rate of 15 cc per minute.In the second intervention group, we place 200 micrograms of misoprostol in the patient's rectal area (It should be noted that Mizoprostol 100 mg tablets are from Abu Reihan Company and 10 units of Oxytocin ampoules are from Alborz Daroo Company). If proper uterine contraction does not occur after a few minutes (maximum 5 minutes), if the initial intervention is not enough, oxytocin will be repeated up to 100 units (inside the Ringer's serum) and if we need more medication, misoprostol. We continue up to 1000 micrograms</i_keyword>
      <i_keyword>Control group: After umbilical cord clamping during surgery, the patient will receive 20 oxytocin units within half a liter of Ringer's serum at a rate of 15 cc per minute(It should be noted that the oxytocin ampoule is 10 units from Alborz Daroo Co.) . If proper uterine contraction does not occur after a few minutes (maximum 5 minutes), oxytocin is repeated for up to 100 units (inside the Ringer's serum).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Bleeding during cesarean section. Timepoint: Bleeding is removed during surgery and after surgery. Method of measurement: The amount of blood lost in each group at the end of the operation, based on the amount of blood in the suction and the estimated blood volume absorbed by each gauze and long gauze with the scales before and after The operation is weighed and the amount of clot excreted from the vagina after uterine massage is calculated at the end of the operation and will be recorded in the desired checklist.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-04-29</approval_date>
        <contact_name>Ethics Committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>Sari, Farahabad Road, Mazandaran University of Medical Sciences, School of Paramedical Sciences Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
